About Isofol
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with new dosing regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- April 09, 2025 - April 11, 2025
Årsredovisning 2024, publiceras i vecka 15 i april 2025 - April 09, 2025 - April 11, 2025
Annual report 2024, published in week 15, April 2025 - May 21, 2025 - May 21, 2025
Delårsrapport januari-mars 2025
Media – Lates pressreleases
Isofol expands network of advisors with prominent expert
GOTHENBURG, Sweden, March 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has expanded its network of advisors…
Isofol presents at Stora Aktiedagarna on March 12
GOTHENBURG, Sweden, March 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s CEO will present the company and its…
Isofol presents at several upcoming investor meetings
GOTHENBURG, Sweden, March 5, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company will participate in several investor and partnering…
INVESTORS – latest reports and presentations
Q4 2024
Presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
